Metastatic Castrate-Resistant Prostate Cancer

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Evopoint Biosciences
Evopoint BiosciencesChina - Beijing
1 program
1
XNW5004Phase 1/21 trial
Active Trials
NCT06702995Recruiting307Est. Jul 2026

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
Evopoint BiosciencesXNW5004

Clinical Trials (1)

Total enrollment: 307 patients across 1 trials

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

Start: Apr 2023Est. completion: Jul 2026307 patients
Phase 1/2Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 307 patients
1 companies competing in this space